Diligence memo · auto-generated · as of July 2, 2026

Axikin Pharmaceuticals Inc

Axikin Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Axikin Pharmaceuticals Inc operates in Pharmaceuticals, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Axikin Pharmaceuticals Inc has raised $16M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.5M on 2014-03-12.

Most recent recorded round closed around 2014-03-12.

Valuation (modeled)modeled

Provath models Axikin Pharmaceuticals Inc at approximately $201M (range $7.4M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.03× the median modeled value of Series A Pharmaceuticals companies in 2013–2015 (64 peers) — value vs value, same stage and era. Within the normal band (103% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 15 months.

Last raise 12.3 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 62% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 69% of those peers.

Closest niche peers: Aquinox Pharmaceuticals (Usa) Inc, Neurovia, Inc., Romark Global Pharma, LLC, Access Pharmaceuticals Inc, Minnesota Medical Solutions LLC.

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.